PACS

PACS Group is a rapid-growth post-acute care roll-up: it operated 321 skilled-nursing/assisted-living facilities across 17 states with operational capacity for 35,379 patients as of December 31, 2025. The growth record is striking -- revenue compounded from $2.40B (2022) to $5.29B in FY2025 (+29.4%), operating income jumped 151.6% to $310M and net income rebounded 243.5% to $192M (EPS $1.22, +221.1%). Returns are high at 20.2% ROE, the cash conversion is real ($404M operating cash flow, +10.0%), and debt is modest -- $245M long-term debt and $4.46M current portion against $197M of cash -- with the business funded largely through long-term triple-net leases (averaging 13 years). The acquire-and-improve model is showing results: mature facilities carry a 4.4 QM Star rating and 95% occupancy.

The decisive problem, however, is right in management's own MD&A: PACS disclosed material weaknesses in internal control over financial reporting -- specifically that it 'did not design and maintain effective controls within the revenue process to address the completeness and accuracy of underlying data used to determine routine revenue' and failed to 'timely assess operational trends that could materially impact variable consideration estimates related to revenue recognition.' The CEO and Interim CFO concluded disclosure controls were 'not effective' as of December 31, 2025. These weaknesses sit squarely on revenue -- the very line driving the bull case -- and they are not new; similar weaknesses were disclosed in the prior 10-K (which itself was filed late, on November 19, 2025). An Interim CFO and a late prior-year filing compound the governance concern.